heterozygous

In a report published Friday, Maxim Group analyst Jason Kolbert said that his thesis on Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) remains unchanged for the following reasons: Kalydeco (ivafcaftor) has been approved for children with one of ten gating/conductance mutations, adding an...